Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CACAG + venetoclax versus standard induction or azacitidine + venetoclax in elderly patients with newly diagnosed AML
ChiCTR2500095795Phase 2Recruiting
- Sponsor
- The Fifth Medical Center of the PLA General Hospital
- Start
- Jan 2025
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tucidinostat, azacitidine, aclarubicin, cytarabine, filgrastim and 1 more in acute myeloid leukemia (AML) (2 arms), sponsored by The Fifth Medical Center of the PLA General Hospital. Primary endpoint: Complete remission rate. Started Jan 2025; status: recruiting.
02
Drugs
tucidinostatazacitidineaclarubicincytarabinefilgrastim
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2500095795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095795.